Showing results (31-40 of 76) with videos related to
Sort By:
Pageof 8
Glia|July 24, 2012
The role of insulin-like growth factors signaling in merlin-deficient human schwannomasSylwia Ammoun, M Caroline Schmid, Natalia Ristic, et al.Cancer Research|July 22, 2017
An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid SynthesisDina S Stepanova, Galina Semenova, Yin-Ming Kuo, et al.Ebiomedicine|August 19, 2020
GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningiomaCaterina Negroni, David A Hilton, Emanuela Ercolano, et al.The Laryngoscope|November 21, 2018
Progression of hearing loss in neurofibromatosis type 2 according to genetic severityBeatrice Emmanouil, Rory Houston, Anne May, et al.Ebiomedicine|December 31, 2018
Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolismJemma Dunn, Sara Ferluga, Vikram Sharma, et al.Cancers|November 10, 2020
Integration and Comparison of Transcriptomic and Proteomic Data for MeningiomaJemma Dunn, Vasileios P Lenis, David A Hilton, et al.Neuro-Oncology|June 1, 2010
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannomaSylwia Ammoun, Clare H Cunliffe, Jeffrey C Allen, et al.International Journal of Molecular Sciences|February 20, 2020
A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in <i>AKT1 E17K</i> Mutated TumoursClaire L Adams, Emanuela Ercolano, Sara Ferluga, et al.Cancer Journal (Sudbury, Mass.)|March 6, 2004
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitorYumiko Hirokawa, Anjali Tikoo, John Huynh, et al.Cancers|July 8, 2020
The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient MeningiomaJade Lyons Rimmer, Emanuela Ercolano, Daniele Baiz, et al.Pageof 8